Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Illumina Inc (ILMN)

Illumina Inc (ILMN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 19,719,512
  • Shares Outstanding, K 152,900
  • Annual Sales, $ 4,343 M
  • Annual Income, $ 850,000 K
  • EBIT $ 817 M
  • EBITDA $ 1,087 M
  • 60-Month Beta 1.45
  • Price/Sales 4.56
  • Price/Cash Flow 19.30
  • Price/Book 7.27

Options Overview Details

View History
  • Implied Volatility 43.80% (-0.81%)
  • Historical Volatility 46.65%
  • IV Percentile 41%
  • IV Rank 18.60%
  • IV High 84.13% on 04/08/25
  • IV Low 34.59% on 11/14/25
  • Expected Move (DTE 15) 8.16 (6.36%)
  • Put/Call Vol Ratio 2.03
  • Today's Volume 2,261
  • Volume Avg (30-Day) 3,081
  • Put/Call OI Ratio 0.55
  • Today's Open Interest 36,908
  • Open Int (30-Day) 32,148
  • Expected Range 120.06 to 136.38

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 1.06
  • Number of Estimates 7
  • High Estimate 1.12
  • Low Estimate 1.04
  • Prior Year 0.97
  • Growth Rate Est. (year over year) +9.28%

Price Performance

See More
Period Period Low Period High Performance
1-Month
112.65 +13.84%
on 02/12/26
134.76 -4.84%
on 02/27/26
-5.37 (-4.02%)
since 02/05/26
3-Month
112.65 +13.84%
on 02/12/26
155.53 -17.55%
on 01/22/26
-0.72 (-0.56%)
since 12/05/25
52-Week
68.70 +86.67%
on 04/09/25
155.53 -17.55%
on 01/22/26
+42.55 (+49.66%)
since 03/05/25

Most Recent Stories

More News
Alliance for Genomic Discovery expands with Regeneron Genetics Center membership and new proteomics data offering

Dataset grows to more than 312,000 whole genomes with longitudinal clinical data

ILMN : 128.24 (-0.57%)
Illumina whole-genome sequencing technology to accelerate rare disease testing in Florida

Increased adoption of clinical whole-genome sequencing is advancing diagnostics for rare diseases, which affect 15 million American children

ILMN : 128.24 (-0.57%)
Illumina Launches TruPath Genome, Unveils NovaSeq X Roadmap, and Drives Cancer Breakthroughs with Connected Multiomics

SAN DIEGO , Feb. 26, 2026 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a suite of powerful advancements that will...

ILMN : 128.24 (-0.57%)
Illumina partners go beyond the genome, driving cancer breakthroughs using spatial transcriptomics, epigenomics, and proteomics

At AGBT, researchers reveal new findings from studies leveraging Illumina's multiomics solutions

ILMN : 128.24 (-0.57%)
Illumina launches TruPath Genome, setting a new standard in genomic insight

SAN DIEGO , Feb. 24, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the launch of TruPath™ Genome, setting a new standard for high-quality, comprehensive whole genome insights...

ILMN : 128.24 (-0.57%)
Illumina unveils roadmap of groundbreaking NovaSeq X advancements in data quality, output, speed, and flexibility

40% increase in output to 35 billion reads, up to Q70 quality scores, improved turnaround time, and staggered starts are among the updates to be rolled out on all NovaS eq X systems , advancing...

ILMN : 128.24 (-0.57%)
Illumina To Webcast Upcoming Investor Conference

SAN DIEGO , Feb. 17, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that members of its management team will participate at the following investor conference:

ILMN : 128.24 (-0.57%)
1 Healthcare Stock Worth Your Attention and 2 Facing Challenges

1 Healthcare Stock Worth Your Attention and 2 Facing Challenges

ILMN : 128.24 (-0.57%)
MOH : 147.71 (-1.55%)
REGN : 764.93 (-2.87%)
5 Insightful Analyst Questions From Illumina’s Q4 Earnings Call

5 Insightful Analyst Questions From Illumina’s Q4 Earnings Call

ILMN : 128.24 (-0.57%)
Stocks Roar Back as Beaten-Down Tech Sector Rebounds

The S&P 500 Index ($SPX ) (SPY ) on Friday closed up +1.97%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +2.47%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +2.15%. March E-mini S&P...

MSTR : 139.81 (-4.53%)
AMAT : 346.53 (-3.14%)
AVGO : 332.74 (+4.79%)
HIMS : 15.88 (-3.47%)
GLXY : 22.73 (-6.61%)
$IUXX : 25,020.41 (-0.29%)
COIN : 205.71 (-1.54%)
ASML : 1,368.36 (-2.22%)
ZNM26 : 112-120 (-0.39%)
ESH26 : 6,823.00 (-0.77%)
STX : 367.34 (-2.05%)
AMD : 199.45 (-1.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Illumina Inc. is a life sciences company, which provides tools and integrated systems for analysis of genetic variation and function. Using its proprietary technologies, the company provides innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies,...

See More

Key Turning Points

3rd Resistance Point 134.99
2nd Resistance Point 133.64
1st Resistance Point 131.30
Last Price 128.24
1st Support Level 127.62
2nd Support Level 126.27
3rd Support Level 123.93

See More

52-Week High 155.53
Last Price 128.24
Fibonacci 61.8% 122.36
Fibonacci 50% 112.11
Fibonacci 38.2% 101.87
52-Week Low 68.70

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar